• Overview
  • Eligibility
  • More info
  • Locations

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis (NCT02770170)

The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.
  • Drug: BI 655064 dose 1
    • Drug: BI 655064 dose 2
      • Drug: BI 655064 dose 3
        • Drug: Placebo
          Ages eligible for Study
          18 Years to 70 Years
          Genders eligible for Study
          All
          Accepts Healthy Volunteers
          No

          85 locations

          Status:
          recruiting
          Type:
          Interventional
          Phase:
          Start:
          15 May, 2016
          Updated:
          02 April, 2018
          Participants:
          120
          Apply
          A girl giving information about available additional trials.

          FindMeCure helps you find, understand and join clinical trials from all over the world.

          There are more clinical trials for your condition!